{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+cell+transplantation&page=10",
    "query": {
      "intervention": "Blood cell transplantation",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 1780,
    "total_pages": 178,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+cell+transplantation&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood+cell+transplantation&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T19:11:28.680Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003838",
      "title": "Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloproliferative Disorders",
        "Acute Myelogenous Leukemia",
        "Chronic Myelogenous Leukemia",
        "Myelodysplastic Syndrome",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "T-cell replete PBPC allograft",
          "type": "PROCEDURE"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "2 Years to 80 Years"
      },
      "enrollment_count": 202,
      "start_date": "1999-04-15",
      "completion_date": "2020-06-18",
      "has_results": true,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-14T19:11:28.680Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003838"
    },
    {
      "nct_id": "NCT07365306",
      "title": "Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent Primary Mediastinal Large B-Cell Lymphoma",
        "Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory Primary Mediastinal Large B-Cell Lymphoma",
        "Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Epcoritamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2026-07-27",
      "completion_date": "2029-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-14T19:11:28.680Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Newnan, Georgia • Zion, Illinois",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        },
        {
          "city": "Zion",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07365306"
    },
    {
      "nct_id": "NCT00006054",
      "title": "Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Immunologic Deficiency Syndromes",
        "Chediak-Higashi Syndrome",
        "Common Variable Immunodeficiency",
        "Graft Versus Host Disease",
        "X-Linked Lymphoproliferative Syndrome",
        "Familial Erythrophagocytic Lymphohistiocytosis",
        "Hemophagocytic Lymphohistiocytosis",
        "X-linked Agammaglobulinemia",
        "Wiskott-Aldrich Syndrome",
        "Chronic Granulomatous Disease",
        "X-linked Hyper IgM Syndrome",
        "Severe Combined Immunodeficiency",
        "Leukocyte Adhesion Deficiency Syndrome",
        "Virus-Associated Hemophagocytic Syndrome"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Bone Marrow Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Fairview University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "Up to 35 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-03",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2009-10-15",
      "last_synced_at": "2026-10-14T19:11:28.680Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006054"
    },
    {
      "nct_id": "NCT00856245",
      "title": "Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkins Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2009-02",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-14T19:11:28.680Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00856245"
    },
    {
      "nct_id": "NCT06972069",
      "title": "Tolerance Through Mixed Chimerism (Sip-Tego)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Kidney Failure",
        "Transplant Recipient (Kidney)",
        "Transplant Tolerance",
        "Immunosuppresion",
        "Immunosuppression After Kidney Transplantation"
      ],
      "interventions": [
        {
          "name": "Combined Kidney/Bone Marrow Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Donation of Kidney / Bone Marrow",
          "type": "PROCEDURE"
        },
        {
          "name": "Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Tatsuo Kawai, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2025-05-31",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-14T19:11:28.680Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06972069"
    },
    {
      "nct_id": "NCT00723099",
      "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Aggressive Non-Hodgkin Lymphoma",
        "Chronic Myelogenous Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Indolent Non-Hodgkin Lymphoma",
        "Lymphoma",
        "Mixed Phenotype Acute Leukemia",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Follicular Lymphoma",
        "Recurrent Lymphoplasmacytic Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Plasma Cell Myeloma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Recurrent T-Cell Non-Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Chronic Myelogenous Leukemia",
        "Refractory Follicular Lymphoma",
        "Refractory Hodgkin Lymphoma",
        "Refractory Lymphoplasmacytic Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Small Lymphocytic Lymphoma",
        "T-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "Up to 69 Years"
      },
      "enrollment_count": 73,
      "start_date": "2008-06-25",
      "completion_date": "2018-07-31",
      "has_results": true,
      "last_update_posted_date": "2019-12-27",
      "last_synced_at": "2026-10-14T19:11:28.680Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Denver, Colorado • Salt Lake City, Utah + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00723099"
    },
    {
      "nct_id": "NCT00052884",
      "title": "Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug/Agent Toxicity by Tissue/Organ",
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "bone marrow ablation with stem cell support",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2004-01-22",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-10-14T19:11:28.680Z",
      "location_count": 16,
      "location_summary": "Scottsdale, Arizona • Indianapolis, Indiana • Burnsville, Minnesota + 12 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Burnsville",
          "state": "Minnesota"
        },
        {
          "city": "Coon Rapids",
          "state": "Minnesota"
        },
        {
          "city": "Edina",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00052884"
    },
    {
      "nct_id": "NCT00002649",
      "title": "Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "bone marrow ablation with stem cell support",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "16 Years to 60 Years"
      },
      "enrollment_count": 206,
      "start_date": "1995-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-28",
      "last_synced_at": "2026-10-14T19:11:28.680Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002649"
    },
    {
      "nct_id": "NCT01565616",
      "title": "Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Conditioning Regimen with Bone Marrow Transplant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "16 Years to 40 Years"
      },
      "enrollment_count": 22,
      "start_date": "2012-03",
      "completion_date": "2016-06-30",
      "has_results": true,
      "last_update_posted_date": "2017-11-21",
      "last_synced_at": "2026-10-14T19:11:28.680Z",
      "location_count": 8,
      "location_summary": "Oakland, California • Washington D.C., District of Columbia • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01565616"
    },
    {
      "nct_id": "NCT00448357",
      "title": "Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "rabbit anti-thymocyte globulin (ATG)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2005-10",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-07-17",
      "last_synced_at": "2026-10-14T19:11:28.680Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00448357"
    }
  ]
}